Intratumoral injection of melatonin enhances tumor regression in cell line-derived and patient-derived xenografts of head and neck cancer by increasing mitochondrial oxidative stress
Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved..
Head and neck squamous cell carcinoma present a high mortality rate. Melatonin has been shown to have oncostatic effects in different types of cancers. However, inconsistent results have been reported for in vivo applications. Consequently, an alternative administration route is needed to improve bioavailability and establish the optimal dosage of melatonin for cancer treatment. On the other hand, the use of patient-derived tumor models has transformed the field of drug research because they reflect the heterogeneity of patient tumor tissues. In the present study, we explore mechanisms for increasing melatonin bioavailability in tumors and investigate its potential as an adjuvant to improve the therapeutic efficacy of cisplatin in the setting of both xenotransplanted cell lines and primary human HNSCC. We analyzed the effect of two different formulations of melatonin administered subcutaneously or intratumorally in Cal-27 and SCC-9 xenografts and in patient-derived xenografts. Melatonin effects on tumor mitochondrial metabolism was also evaluated as well as melatonin actions on tumor cell migration. In contrast to the results obtained with the subcutaneous melatonin, intratumoral injection of melatonin drastically inhibited tumor progression in HNSCC-derived xenografts, as well as in patient-derived xenografts. Interestingly, intratumoral injection of melatonin potentiated CDDP effects, decreasing Cal-27 tumor growth. We demonstrated that melatonin increases ROS production and apoptosis in tumors, targeting mitochondria. Melatonin also reduces migration capacities and metastasis markers. These results illustrate the great clinical potential of intratumoral melatonin treatment and encourage a future clinical trial in cancer patients to establish a proper clinical melatonin treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:167 |
|---|---|
| Enthalten in: |
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 167(2023) vom: 01. Nov., Seite 115518 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Martinez-Ruiz, Laura [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cisplatin |
|---|
| Anmerkungen: |
Date Completed 23.10.2023 Date Revised 23.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.biopha.2023.115518 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362145601 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362145601 | ||
| 003 | DE-627 | ||
| 005 | 20231226090632.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biopha.2023.115518 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1207.xml |
| 035 | |a (DE-627)NLM362145601 | ||
| 035 | |a (NLM)37717534 | ||
| 035 | |a (PII)S0753-3322(23)01316-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Martinez-Ruiz, Laura |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Intratumoral injection of melatonin enhances tumor regression in cell line-derived and patient-derived xenografts of head and neck cancer by increasing mitochondrial oxidative stress |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.10.2023 | ||
| 500 | |a Date Revised 23.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved. | ||
| 520 | |a Head and neck squamous cell carcinoma present a high mortality rate. Melatonin has been shown to have oncostatic effects in different types of cancers. However, inconsistent results have been reported for in vivo applications. Consequently, an alternative administration route is needed to improve bioavailability and establish the optimal dosage of melatonin for cancer treatment. On the other hand, the use of patient-derived tumor models has transformed the field of drug research because they reflect the heterogeneity of patient tumor tissues. In the present study, we explore mechanisms for increasing melatonin bioavailability in tumors and investigate its potential as an adjuvant to improve the therapeutic efficacy of cisplatin in the setting of both xenotransplanted cell lines and primary human HNSCC. We analyzed the effect of two different formulations of melatonin administered subcutaneously or intratumorally in Cal-27 and SCC-9 xenografts and in patient-derived xenografts. Melatonin effects on tumor mitochondrial metabolism was also evaluated as well as melatonin actions on tumor cell migration. In contrast to the results obtained with the subcutaneous melatonin, intratumoral injection of melatonin drastically inhibited tumor progression in HNSCC-derived xenografts, as well as in patient-derived xenografts. Interestingly, intratumoral injection of melatonin potentiated CDDP effects, decreasing Cal-27 tumor growth. We demonstrated that melatonin increases ROS production and apoptosis in tumors, targeting mitochondria. Melatonin also reduces migration capacities and metastasis markers. These results illustrate the great clinical potential of intratumoral melatonin treatment and encourage a future clinical trial in cancer patients to establish a proper clinical melatonin treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Head and neck cancer | |
| 650 | 4 | |a Intratumoral injection | |
| 650 | 4 | |a Melatonin | |
| 650 | 4 | |a Mitochondria | |
| 650 | 4 | |a Patient-derived xenograft | |
| 650 | 4 | |a Reactive oxygen species | |
| 650 | 7 | |a Melatonin |2 NLM | |
| 650 | 7 | |a JL5DK93RCL |2 NLM | |
| 650 | 7 | |a Cisplatin |2 NLM | |
| 650 | 7 | |a Q20Q21Q62J |2 NLM | |
| 700 | 1 | |a Florido, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez-Santana, César |e verfasserin |4 aut | |
| 700 | 1 | |a López-Rodríguez, Alba |e verfasserin |4 aut | |
| 700 | 1 | |a Guerra-Librero, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Gil, Beatriz I |e verfasserin |4 aut | |
| 700 | 1 | |a García-Tárraga, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia-Verdugo, José Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Oppel, Felix |e verfasserin |4 aut | |
| 700 | 1 | |a Sudhoff, Holger |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez-Porras, David |e verfasserin |4 aut | |
| 700 | 1 | |a Ten-Steve, Amadeo |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Martínez, José |e verfasserin |4 aut | |
| 700 | 1 | |a González-García, Pilar |e verfasserin |4 aut | |
| 700 | 1 | |a Rusanova, Iryna |e verfasserin |4 aut | |
| 700 | 1 | |a Acuña-Castroviejo, Darío |e verfasserin |4 aut | |
| 700 | 1 | |a Carriel, Víctor |e verfasserin |4 aut | |
| 700 | 1 | |a Escames, Germaine |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie |d 1984 |g 167(2023) vom: 01. Nov., Seite 115518 |w (DE-627)NLM012645591 |x 1950-6007 |7 nnns |
| 773 | 1 | 8 | |g volume:167 |g year:2023 |g day:01 |g month:11 |g pages:115518 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.biopha.2023.115518 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 167 |j 2023 |b 01 |c 11 |h 115518 | ||